Chronic News and Research

RSS

Hyperion's HPN-100 granted FDA Fast Track Designation for urea cycle disorders

Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.

18 Oct 2010

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.

18 Oct 2010

MSF calls for donor countries to improve food aid nutrition standards on eve of World Food Day

Medecins Sans Frontieres (MSF) released a statement in advance of Saturday's World Food Day saying that the "world's biggest donors of food aid ... continued to supply and fund nutritionally 'substandard' food to developing countries, despite scientific evidence showing it was of little value in reducing child malnutrition," Reuters AlertNet reports.

18 Oct 2010

IASP sponsors campaign for acute pain management

The Global Year Against Acute Pain launches today, focusing attention on a widely under-assessed and undertreated pain that affects most people throughout their lives. Sponsored by the International Association for the Study of Pain (IASP), the 12-month campaign focuses on education for health care professional and government leaders as well as public awareness to help lessen the gap between existing knowledge and technology for acute pain control and current pain management practice.

18 Oct 2010

Study distinguishes 4 groups of pathological gamblers

Disorganised and emotionally unstable, poorly adapted, suffering from alcohol problems, impulsive, or with a "globally adapted" personality. These are the features of the four diagnosed types of compulsive gamblers identified by researchers at the University Hospital of Bellvitge (IDIBELL) and the Autonomous University of Barcelona (UAB). According to the scientific team, only one of these four shows signs of a significant pathology.

18 Oct 2010

Botox receives FDA approval for treatment of chronic migraine

The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine. Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.

18 Oct 2010

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Biogen Idec and Elan Corporation, plc today announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum.

18 Oct 2010

FDA plans to revoke knee implant approval following intense political pressure for its approval

The Food and Drug Administration on Thursday said it planned to revoke a medical-device company's right to sell a knee implant called Menaflex after an unprecedented yearlong review concluded the agency erred in allowing it on the market

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Teva Pharmaceutical announces new data from PreCISe study

Teva Pharmaceutical Industries Ltd. today announced new data from the five-year extension of the PreCISe study demonstrating that earlier initiation of treatment with Copaxone (glatiramer acetate injection) in patients presenting with first signs of multiple sclerosis (MS), provided greater effects in delaying conversion to clinically definite MS (CDMS) compared to later treatment initiation after diagnosis of CDMS or after three years on the study.

18 Oct 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of epilepsy seen in infancy and early childhood.

15 Oct 2010

Report examines impact of federal stimulus funding on health spending in Florida

The Collins Center for Public Policy has released a report that examines the impact of the federal government's economic stimulus funding on Florida's health care system.

15 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

$Spinal fractures remain undiagnosed and untreated$

Spinal fractures remain undiagnosed and untreated

A new report issued by the International Osteoporosis Foundation (IOF) for World Osteoporosis Day puts the spotlight on the severe impact of spinal fractures and calls on health professionals to recognize the signs of these fractures in their patients.

15 Oct 2010

Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference

Discovery Laboratories, Inc. today announces that the Phase 2a clinical study of aerosolized KL4 surfactant (lucinactant) in patients with cystic fibrosis (CF) has completed and the results from the study will be presented at the upcoming North American Cystic Fibrosis Conference (NACFC; October 21-23, 2010).

15 Oct 2010

LifeBridge Health reveals two ways to prevent seasonal flu

You're having that dreaded feeling. Your muscles are aching, you've got a a fever and sore throat . Get ready: It is flu season again! The flu is a respiratory virus that's contagious. In addition to the symptoms above, a, cough and headache, as well as diarrhea may indicate the virus is present.

15 Oct 2010

Study suggests treating RLS may improve sleep and quality of life in people with fibromyalgia

A study in the Oct. 15, 2010 issue of the Journal of Clinical Sleep Medicine found that adults with fibromyalgia had a much higher prevalence and risk of restless legs syndrome than healthy controls. The study suggests that treating RLS may improve sleep and quality of life in people with fibromyalgia.

15 Oct 2010

UCB announces winners of 2010 UCB Crohn's and Me Scholarship Program

UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Crohn's and Me Scholarship Program for outstanding individuals affected by this condition. UCB has selected 31 winners to receive a scholarship worth up to $10,000 to help them seek personal growth through higher education.

15 Oct 2010

Chronic News and Research

Hyperion's HPN-100 granted FDA Fast Track Designation for urea cycle disorders

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

MSF calls for donor countries to improve food aid nutrition standards on eve of World Food Day

IASP sponsors campaign for acute pain management

Study distinguishes 4 groups of pathological gamblers

Botox receives FDA approval for treatment of chronic migraine

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

FDA plans to revoke knee implant approval following intense political pressure for its approval

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Teva Pharmaceutical announces new data from PreCISe study

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Report examines impact of federal stimulus funding on health spending in Florida

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Spinal fractures remain undiagnosed and untreated

Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference

LifeBridge Health reveals two ways to prevent seasonal flu

Study suggests treating RLS may improve sleep and quality of life in people with fibromyalgia

UCB announces winners of 2010 UCB Crohn's and Me Scholarship Program

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News